Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

22 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Liver-directed drugs for transthyretin-mediated amyloidosis.
Brannagan TH 3rd, Berk JL, Gillmore JD, Maurer MS, Waddington-Cruz M, Fontana M, Masri A, Obici L, Brambatti M, Baker BF, Hannan LA, Buchele G, Viney NJ, Coelho T, Nativi-Nicolau J. Brannagan TH 3rd, et al. Among authors: viney nj. J Peripher Nerv Syst. 2022 Dec;27(4):228-237. doi: 10.1111/jns.12519. Epub 2022 Nov 16. J Peripher Nerv Syst. 2022. PMID: 36345805 Free PMC article. Review.
Ligand conjugated antisense oligonucleotide for the treatment of transthyretin amyloidosis: preclinical and phase 1 data.
Viney NJ, Guo S, Tai LJ, Baker BF, Aghajan M, Jung SW, Yu RZ, Booten S, Murray H, Machemer T, Burel S, Murray S, Buchele G, Tsimikas S, Schneider E, Geary RS, Benson MD, Monia BP. Viney NJ, et al. ESC Heart Fail. 2021 Feb;8(1):652-661. doi: 10.1002/ehf2.13154. Epub 2020 Dec 7. ESC Heart Fail. 2021. PMID: 33283485 Free PMC article. Clinical Trial.
Design and Rationale of the Global Phase 3 NEURO-TTRansform Study of Antisense Oligonucleotide AKCEA-TTR-LRx (ION-682884-CS3) in Hereditary Transthyretin-Mediated Amyloid Polyneuropathy.
Coelho T, Ando Y, Benson MD, Berk JL, Waddington-Cruz M, Dyck PJ, Gillmore JD, Khella SL, Litchy WJ, Obici L, Monteiro C, Tai LJ, Viney NJ, Buchele G, Brambatti M, Jung SW, St L O'Dea L, Tsimikas S, Schneider E, Geary RS, Monia BP, Gertz M. Coelho T, et al. Among authors: viney nj. Neurol Ther. 2021 Jun;10(1):375-389. doi: 10.1007/s40120-021-00235-6. Epub 2021 Feb 26. Neurol Ther. 2021. PMID: 33638113 Free PMC article.
IONIS-PKKRx a Novel Antisense Inhibitor of Prekallikrein and Bradykinin Production.
Ferrone JD, Bhattacharjee G, Revenko AS, Zanardi TA, Warren MS, Derosier FJ, Viney NJ, Pham NC, Kaeser GE, Baker BF, Schneider E, Hughes SG, Monia BP, MacLeod AR. Ferrone JD, et al. Among authors: viney nj. Nucleic Acid Ther. 2019 Apr;29(2):82-91. doi: 10.1089/nat.2018.0754. Epub 2019 Feb 28. Nucleic Acid Ther. 2019. PMID: 30817230 Free PMC article.
Antisense Inhibition of Prekallikrein to Control Hereditary Angioedema.
Cohn DM, Viney NJ, Fijen LM, Schneider E, Alexander VJ, Xia S, Kaeser GE, Nanavati C, Baker BF, Geary RS, Levi M, Meijers JCM, Stroes ESG. Cohn DM, et al. Among authors: viney nj. N Engl J Med. 2020 Sep 24;383(13):1242-1247. doi: 10.1056/NEJMoa1915035. Epub 2020 Sep 2. N Engl J Med. 2020. PMID: 32877578 Clinical Trial.
Antisense Inhibition of Apolipoprotein C-III in Patients with Hypertriglyceridemia.
Gaudet D, Alexander VJ, Baker BF, Brisson D, Tremblay K, Singleton W, Geary RS, Hughes SG, Viney NJ, Graham MJ, Crooke RM, Witztum JL, Brunzell JD, Kastelein JJ. Gaudet D, et al. Among authors: viney nj. N Engl J Med. 2015 Jul 30;373(5):438-47. doi: 10.1056/NEJMoa1400283. N Engl J Med. 2015. PMID: 26222559 Free article. Clinical Trial.
22 results